Anti-SHP1 (phospho Y536) antibody (ab131500)
Key features and details
- Rabbit polyclonal to SHP1 (phospho Y536)
- Suitable for: IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-SHP1 (phospho Y536) antibody
See all SHP1 primary antibodies -
Description
Rabbit polyclonal to SHP1 (phospho Y536) -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide corresponding to Human SHP1 (phospho Y536) conjugated to keyhole limpet haemocyanin.
Database link: NP_002822.2 -
Positive control
- HeLa cells; Human breast carcinoma tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride
PBS without Mg2+ and Ca2+ -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab131500 was purified by affinity chromatography using epitope specific phosphopeptide. Non-phosphospecific antibodies were removed by chromatography using non-phosphopeptide. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab131500 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/50 - 1/100.
|
|
ICC/IF |
1/100 - 1/200.
|
Notes |
---|
IHC-P
1/50 - 1/100. |
ICC/IF
1/100 - 1/200. |
Target
-
Function
Plays a key role in hematopoiesis. This PTPase activity may directly link growth factor receptors and other signaling proteins through protein-tyrosine phosphorylation. The SH2 regions may interact with other cellular components to modulate its own phosphatase activity against interacting substrates. Together with MTUS1, induces UBE2V2 expression upon angiotensin II stimulation. -
Tissue specificity
Isoform 1 is expressed in hematopoietic cells. Isoform 2 is expressed in non-hematopoietic cells. -
Sequence similarities
Belongs to the protein-tyrosine phosphatase family. Non-receptor class 2 subfamily.
Contains 2 SH2 domains.
Contains 1 tyrosine-protein phosphatase domain. -
Post-translational
modificationsPhosphorylated on serine and tyrosine residues. -
Cellular localization
Cytoplasm. Nucleus. In neurons, translocates into the nucleus after treatment with angiotensin II. - Information by UniProt
-
Database links
- Entrez Gene: 5777 Human
- Omim: 176883 Human
- SwissProt: P29350 Human
- Unigene: 63489 Human
-
Alternative names
- 70Z-SHP antibody
- EC 3.1.3.48 antibody
- HCP antibody
see all
Images
-
Immunofluorescent analysis of methanol-fixed HeLa cells labelling SHP1 (phospho Y536) with ab131500 at 1/100 dilution.
-
Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling SHP1 (phospho Y536) with ab131500 at 1/50 dilution (left) or ab131500 preincubated with blocking peptide (right).
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab131500 has been referenced in 4 publications.
- Flores AM et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat Nanotechnol 15:154-161 (2020). PubMed: 31988506
- Gerlach BD et al. Resolvin D1 promotes the targeting and clearance of necroptotic cells. Cell Death Differ 27:525-539 (2020). PubMed: 31222041
- Kojima Y et al. Proefferocytic Therapy Promotes Transforming Growth Factor-ß Signaling and Prevents Aneurysm Formation. Circulation 137:750-753 (2018). PubMed: 29440201
- Kojima Y et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86-90 (2016). PubMed: 27437576